-
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
Histol Histopathol. 2009 May;24(5):643-50
PMID: 19283671
-
Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines.
In Vitro. 1984 Nov;20(11):856-8
PMID: 6519667
-
dbSNP: the NCBI database of genetic variation.
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
PMID: 11125122
-
Genetic risk factors for melanoma.
Hum Genet. 2009 Oct;126(4):499-510
PMID: 19585149
-
Database resources of the National Center for Biotechnology Information.
Nucleic Acids Res. 2009 Jan;37(Database issue):D5-15
PMID: 18940862
-
MicroRNA-dependent regulation of cKit in cutaneous melanoma.
Biochem Biophys Res Commun. 2009 Feb 13;379(3):790-4
PMID: 19126397
-
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
Cancer Res. 2009 Apr 15;69(8):3241-4
PMID: 19351826
-
KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells.
Oncogene. 1993 Aug;8(8):2221-9
PMID: 7687762
-
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms.
Cancer Res. 2008 Apr 15;68(8):2745-54
PMID: 18417445
-
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
Int J Cancer. 2009 Feb 15;124(4):862-8
PMID: 19035443
-
Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes.
J Invest Dermatol. 2006 May;126(5):1102-10
PMID: 16410786
-
Evolutionary conservation of microRNA regulatory circuits: an examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny.
DNA Cell Biol. 2007 Apr;26(4):209-18
PMID: 17465887
-
c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas.
Mol Biol Cell. 1992 Feb;3(2):197-209
PMID: 1372524
-
Prevalence of KIT expression in human tumors.
J Clin Oncol. 2004 Nov 15;22(22):4514-22
PMID: 15542802
-
Major response to imatinib mesylate in KIT-mutated melanoma.
J Clin Oncol. 2008 Apr 20;26(12):2046-51
PMID: 18421059
-
MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.
Pharmacogenomics. 2009 Mar;10(3):399-416
PMID: 19290790
-
Roles of microRNAs and their targets in cancer.
Expert Opin Biol Ther. 2007 Dec;7(12):1833-40
PMID: 18034649
-
Trends in dermatology: melanoma incidence.
Arch Dermatol. 2010 Mar;146(3):318
PMID: 20231504
-
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
N Engl J Med. 2002 Aug 15;347(7):472-80
PMID: 12181401
-
Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Oncogene. 1996 Dec 5;13(11):2339-47
PMID: 8957075
-
Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer.
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1502-5
PMID: 19164563
-
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3
PMID: 18510589
-
The role of microRNA genes in papillary thyroid carcinoma.
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80
PMID: 16365291
-
Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.
EMBO J. 1998 Aug 3;17(15):4358-69
PMID: 9687504
-
microRNAs and cancer: an overview.
Cell Cycle. 2008 Aug 15;7(16):2485-92
PMID: 18719380
-
ALFRED: an allele frequency database for microevolutionary studies.
Evol Bioinform Online. 2007 Feb 22;1:1-10
PMID: 19325849
-
Epstein-Barr virus-mediated dysregulation of human microRNA expression.
Cell Cycle. 2008 Nov 15;7(22):3595-600
PMID: 19001862
-
Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Clin Cancer Res. 2008 Dec 1;14(23):7726-32
PMID: 19047099
-
Loss of c-kit expression in cultured melanoma cells.
Oncogene. 1992 Jan;7(1):51-6
PMID: 1371338
-
2010 TNM staging system for cutaneous melanoma...and beyond.
Ann Surg Oncol. 2010 Jun;17(6):1475-7
PMID: 20300965
-
Somatic activation of KIT in distinct subtypes of melanoma.
J Clin Oncol. 2006 Sep 10;24(26):4340-6
PMID: 16908931
-
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.
Cancer Res. 2009 Sep 15;69(18):7459-65
PMID: 19738052
-
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Cancer Res. 2010 Aug 15;70(16):6509-15
PMID: 20647319
-
Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.
Int J Cancer. 1992 Sep 9;52(2):197-201
PMID: 1381702
-
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
Cancer Res. 2008 Oct 15;68(20):8535-40
PMID: 18922928
-
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 2008 Jul 15;68(14):5743-52
PMID: 18632627